Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Milei Threatens Falkland Oil Firms With Sanctions 
(4) - EconoTimes)
Add as a preferred source on Google
CHESTERBROOK, Pa., March 02, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of February 19, 2018, the grant of inducement stock options to purchase an aggregate of 95,000 shares of the Company’s common stock to two new employees. These awards were granted pursuant to the Trevena, Inc. Inducement Plan as an inducement material to the new employees entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4).
The first stock option, for 47,500 shares, has an exercise price per share of $1.64, the closing stock price on February 20, 2018; the second stock option, also for 47,500 shares, has an exercise price per share of $1.79, the closing stock price on February 28, 2018. Each option has a ten-year term and will vest with respect to one-sixteenth of the total number of shares subject to the option on each quarterly anniversary of the respective grant dates.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
SVP, scientific affairs and investor relations officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
